Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Stefan Zimmermann

ESMO Council: Press & Media Affairs Committee Chair


Centre Hospitalier Universitaire Vaudois (CHUV)
Oncology Department
Service of Immuno-Oncology

Stefan Zimmermann serves as associate head of the Innovative Therapies Unit at the Immuno-oncology service of the University Hospital in Lausanne, Switzerland, a unit dedicated to phase 1 and 2 clinical trials as well as commercial cellular therapies in cancer immunotherapy. His main areas of research and clinical interest are early IO drug development, including T-cell and dendritic cell therapies. Dr Zimmermann is in charge of teaching and patient care and is involved in a portfolio of more than a dozen clinical trials investigating new anticancer agents.

An active member of the Swiss Group for Cancer Research SAKK, he is building partnerships to combine local expertise in translational research with industrial therapeutic innovation. Author of several peer-reviewed manuscripts and book chapters, he serves on the Editorial Board of different clinical cancer journals, and acts as reviewer for multiple cancer immunotherapy publications. He sits on the scientific advisory board of several biotechnology companies.

Dr Zimmermann also serves in the regional Ethics Commission for human research, and participates as faculty in various teaching initiatives in Switzerland.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings